NEW YORK, NY — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed for a registrational clinical trial evaluating Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD),...

Basel, Switzerland –  Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that its Elecsys® Neurofilament Light Chain (NfL) test has received CE mark approval for the detection of neuroinflammation in patients diagnosed with relapsing remitting multiple sclerosis (RRMS).1 The test brings meaningful innovation to MS disease management, offering clinicians a minimally...

DUBLIN, OXFORD, United Kingdom, and PHILADELPHIA, PA – SynOx Therapeutics Limited (“SynOx”) today announced positive topline results from the pivotal Phase 3 TANGENT study of emactuzumab in adult patients with TGCT. Emactuzumab is a targeted CSF-1R inhibitor that is being developed as a short-course treatment for patients with TGCT, which...